Dyadic Logo Current.jpg
Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform
February 28, 2024 08:30 ET | Dyadic International, Inc.
JUPITER, Fla. and BUNNIK, the Netherlands, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company...
Dyadic Logo Current.jpg
Dyadic מקדמת שיתוף פעולה עם המכון הביולוגי הישראלי (IIBR) להתמקדות באיומים ביולוגיים ופתרונות למחלות מתפתחות
February 23, 2024 02:00 ET | Dyadic International, Inc.
יופיטר, פלורידה ונס-ציונה, ישראל, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc ("דיאדיק" או "החברה") (נאסד"ק: DYAI), חברת ביוטכנולוגיה גלובלית המתמחה בפלטפורמות מיקרוביאליות מתקדמות...
Dyadic Logo Current.jpg
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
February 23, 2024 02:00 ET | Dyadic International, Inc.
JUPITER, Fla. and NES-ZIONA, Israel, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced...
Dyadic Logo Current.jpg
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
February 21, 2024 08:30 ET | Dyadic International, Inc.
JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced...
Dyadic Logo Current.jpg
Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing
February 13, 2024 08:30 ET | Dyadic International, Inc.
JUPITER, Fla. and LELAND, N.C., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Dyadic International Inc. (“Dyadic”, or the “Company”) (Nasdaq: DYAI) and Cygnus Technologies®, part of Maravai LifeSciences®...
Dyadic Logo Current.jpg
Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company
February 06, 2024 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company announced it has signed a...
Dyadic Logo Current.jpg
Dyadic to Attend BIO CEO & Investor Conference and European Industry Events
February 01, 2024 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic Logo Current.jpg
Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference
January 02, 2024 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic Logo Current.jpg
Dyadic Attends Investor Events in December
November 30, 2023 08:30 ET | Dyadic International, Inc.
Dyadic Attends Investor Events in December
Dyadic Logo Current.jpg
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
November 29, 2023 08:30 ET | Dyadic International, Inc.
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate